124 related articles for article (PubMed ID: 19664705)
21. Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery.
Bilensoy E; Gürkaynak O; Doğan AL; Hincal AA
Int J Pharm; 2008 Jan; 347(1-2):163-70. PubMed ID: 17689901
[TBL] [Abstract][Full Text] [Related]
22. Saturated phospholipids promote crystallization but slow down polymorphic transitions in triglyceride nanoparticles.
Bunjes H; Koch MH
J Control Release; 2005 Oct; 107(2):229-43. PubMed ID: 16023752
[TBL] [Abstract][Full Text] [Related]
23. Preparation and stabilization of nifedipine lipid nanoparticles.
Kamiya S; Yamada M; Kurita T; Miyagishima A; Arakawa M; Sonobe T
Int J Pharm; 2008 Apr; 354(1-2):242-7. PubMed ID: 18082344
[TBL] [Abstract][Full Text] [Related]
24. Minoxidil-loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations.
Silva AC; Santos D; Ferreira DC; Souto EB
Pharmazie; 2009 Mar; 64(3):177-82. PubMed ID: 19348340
[TBL] [Abstract][Full Text] [Related]
25. Stability of lipid excipients in solid lipid nanoparticles.
Radomska-Soukharev A
Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589
[TBL] [Abstract][Full Text] [Related]
26. In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation.
Kanzer J; Hupfeld S; Vasskog T; Tho I; Hölig P; Mägerlein M; Fricker G; Brandl M
J Pharm Biomed Anal; 2010 Nov; 53(3):359-65. PubMed ID: 20447794
[TBL] [Abstract][Full Text] [Related]
27. Interaction of lipid nanoparticles with human epidermis and an organotypic cell culture model.
Kuntsche J; Bunjes H; Fahr A; Pappinen S; Rönkkö S; Suhonen M; Urtti A
Int J Pharm; 2008 Apr; 354(1-2):180-95. PubMed ID: 17920216
[TBL] [Abstract][Full Text] [Related]
28. Preparation and characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles.
You J; Wan F; de Cui F; Sun Y; Du YZ; Hu FQ
Int J Pharm; 2007 Oct; 343(1-2):270-6. PubMed ID: 17706383
[TBL] [Abstract][Full Text] [Related]
29. Preparation and characterization of highly stable lipid nanoparticles with amorphous core of tuneable viscosity.
Delmas T; Couffin AC; Bayle PA; de Crécy F; Neumann E; Vinet F; Bardet M; Bibette J; Texier I
J Colloid Interface Sci; 2011 Aug; 360(2):471-81. PubMed ID: 21596385
[TBL] [Abstract][Full Text] [Related]
30. The influence of dipalmitoyl phosphatidylserine on phase behaviour of and cellular response to lyotropic liquid crystalline dispersions.
Shen HH; Crowston JG; Huber F; Saubern S; McLean KM; Hartley PG
Biomaterials; 2010 Dec; 31(36):9473-81. PubMed ID: 20880581
[TBL] [Abstract][Full Text] [Related]
31. Preparation and characterization of stearic acid-pullulan nanoparticles.
Kim IS; Oh IJ
Arch Pharm Res; 2010 May; 33(5):761-7. PubMed ID: 20512475
[TBL] [Abstract][Full Text] [Related]
32. Temperature scanning ultrasonic velocity study of complex thermal transformations in solid lipid nanoparticles.
Awad TS; Helgason T; Kristbergsson K; Weiss J; Decker EA; McClements DJ
Langmuir; 2008 Nov; 24(22):12779-84. PubMed ID: 18925768
[TBL] [Abstract][Full Text] [Related]
33. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology.
Teeranachaideekul V; Junyaprasert VB; Souto EB; Müller RH
Int J Pharm; 2008 Apr; 354(1-2):227-34. PubMed ID: 18242898
[TBL] [Abstract][Full Text] [Related]
34. Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications.
Deng Z; Xu S; Li S
Int J Pharm; 2008 Mar; 351(1-2):236-43. PubMed ID: 18093763
[TBL] [Abstract][Full Text] [Related]
35. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization.
Estella-Hermoso de Mendoza A; Rayo M; Mollinedo F; Blanco-Prieto MJ
Eur J Pharm Biopharm; 2008 Feb; 68(2):207-13. PubMed ID: 17707618
[TBL] [Abstract][Full Text] [Related]
36. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs.
Simovic S; Heard P; Hui H; Song Y; Peddie F; Davey AK; Lewis A; Rades T; Prestidge CA
Mol Pharm; 2009; 6(3):861-72. PubMed ID: 19358600
[TBL] [Abstract][Full Text] [Related]
37. The thermotropic phase behaviour and phase structure of a homologous series of racemic beta-D-galactosyl dialkylglycerols studied by differential scanning calorimetry and X-ray diffraction.
Mannock DA; Collins MD; Kreichbaum M; Harper PE; Gruner SM; McElhaney RN
Chem Phys Lipids; 2007 Jul; 148(1):26-50. PubMed ID: 17524381
[TBL] [Abstract][Full Text] [Related]
38. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability.
Teeranachaideekul V; Müller RH; Junyaprasert VB
Int J Pharm; 2007 Aug; 340(1-2):198-206. PubMed ID: 17482778
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxicity of titanium dioxide nanoparticles in mouse fibroblast cells.
Jin CY; Zhu BS; Wang XF; Lu QH
Chem Res Toxicol; 2008 Sep; 21(9):1871-7. PubMed ID: 18680314
[TBL] [Abstract][Full Text] [Related]
40. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles.
Venkateswarlu V; Manjunath K
J Control Release; 2004 Mar; 95(3):627-38. PubMed ID: 15023472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
